Use of recombinant Bm95 isolated from an Argentinean strain of Rhiphicephalus microplus A as a vaccine candidate to control the tick infestation in India was investigated. Recombinant Bm95 expressed ...in yeast, Pichia pastoris. Purified protein blended into a vaccine using aluminium hydroxide as an adjuvant. An adverse effect on the reproduction of ticks was observed in vaccinated animals indicating reduced the environmental contamination and source of infestation indicating its use of Bm95 in the immunological control of ticks in India.
ABSTRACT
Quantification of hepatitis B surface antigen (HBsAg) or relative
in vitro
potency in the final vaccines is a prerequisite for hepatitis B vaccine batch release. The commercial kit for ...automated analysis (AxSYM) is expensive, and an alternative is required for the estimation of HBsAg in hepatitis B vaccines. Mouse monoclonal antibodies (MAbs) specific for HBsAg were developed and characterized. One of the monoclonal antibodies (HBs06) was used in development of an immunocapture ELISA (IC-ELISA) as an unlabeled capture antibody and biotin-labeled detection antibody. The IC-ELISA was standardized and validated using experimental hepatitis B vaccine batches with various HBsAg concentrations per dose and commercial vaccines. The vaccine was treated with an alkaline solubilizer to desorb the HBsAg from Algel-adjuvanted vaccines before testing, and the sensitivity of the test was 5 ng/ml. A good correlation could be observed between the HBsAg estimates derived by both formats, except for the higher HBsAg concentration range, where the IC-ELISA format could estimate closer to the actual values than AxSYM. There was a significant correlation between the estimated relative potencies of the two methods. There was lack of correlation between the
in vivo
potency and the relative
in vitro
potency. However, the estimates of IC-ELISA were comparable to the
in vivo
values when compared with the estimates of AxSYM. The IC-ELISA can therefore be considered to be a reliable test for deriving
in vitro
relative potency and antigen concentration in vaccine batches for batch control and release.
Recombinant antibody phage display technology is a vital tool that facilitates identification of specific binding molecules to a target enabling the rapid generation and selection of high affinity, ...fully human, or mouse antibody product candidates essentially directed towards disease target appropriate for antibody therapy. In this study, a recombinant single-chain Fv antibody fragment (scFv) A11 was isolated from immune spleen cells obtained from mice immunized with inactivated rabies virus (Pasteur strain) using standard methodology and was characterized for its specificity towards the rabies virus glycoprotein. Epitope mapping using peptide libraries and truncated glycoprotein polypeptides suggested that A11 bound to the antigenic site II of rabies glycoprotein against which a majority of rabies virus neutralizing antibodies are directed. The use of the above technology could, therefore, allow development of scFvs with different specificities against the rabies glycoprotein as an alternative to the more cumbersome protocols used for the development of monoclonal antibodies.
Pet skupina po deset životinja cijepljeno je različitim kombinacijama vakcina. Prva je skupina cijepljena polivalentnim cjepivom koje je sadržavalo antigene virusa slinavke i šapa, virusa bjesnoće te ...bakterija Pasteurella multocida i Clostridium chauvoei. Ostale su skupine cijepljene pojedinačnim antigenima, pa je tako druga skupina cijepljena antigenima virusa slinavke i šapa, treća antigenima virusa bjesnoće, četvrta antigenima bakterije Pasteurella multocida, a peta antigenima bakterije Clostridium chauvoei. Serološki odgovor svih životinja provjeren je 21. i 90. dana nakon cijepljenja. Na osnovi serološkoga odgovora nisu utvrđene značajne razlike među različitim načinima cijepljenja.
PDF
